Clinical Trials

86 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05286060 2026-02-09

GENUINE

56 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05980000 2026-02-06

Rambro2

37 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05814666 2026-01-30

PEMDA-HN

69 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck

NCT02769520 2026-01-28

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

78 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT04858269 2026-01-28

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

36 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT04862455 2026-01-23

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

14 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05420948 2025-12-22

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

30 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04414540 2025-12-19

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

20 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04811027 2025-12-11

TACTI-003

171 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04454489 2025-11-19

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

21 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT04854499 2025-11-19

ELEVATE HNSCC

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT03049618 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

42 enrolled 40 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04643379 2025-10-22

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT06161545 2025-10-20

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

40 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05996523 2025-10-03

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

16 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02841748 2025-10-01

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

100 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04260126 2025-10-01

VERSATILE002

95 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05061420 2025-09-22

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

59 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT04369937 2025-09-11

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

18 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05323656 2025-09-02

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

55 enrolled 32 charts

Squamous Cell Carcinoma of Head and Neck

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

172 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04675294 2025-08-01

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

189 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05980598 2025-08-01

BelieveIT-201

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02892201 2025-07-29

Pembrolizumab in HNSCC With Residual Disease After Radiation

9 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03645928 2025-06-19

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

DermatologicHead & NeckThoracic

245 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04633278 2025-05-11

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Head and Neck Neoplasms

NCT05913388 2025-03-11

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma